Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 91 of the 92 references it cites were found in a registry or an index.
Abstract
AIMS: A variety of basal insulin preparations are used to treat patients with type 2 diabetes mellitus (T2DM). We aimed to summarize scientific evidence on relative efficacy and safety of insulin glargine (IGlar) and other insulins in T2DM. METHODS: A systematic review was carried out in major medical databases up to December 2012. Relevant studies compared efficacy and safety of IGlar, added to oral drugs (OAD) or/and in combination with bolus insulin, with protamine insulin (NPH) or premixed insulin (MIX) in the same regimen, as well as with insulin detemir (IDet), in T2DM. Target HbA1c level without hypoglycemic events was considered the primary endpoint. RESULTS: Twenty eight RCTs involving 12,669 T2DM patients followed for 12-52 weeks were included in quantitative analysis. IGlar + OAD use was associated with higher probability of reaching target HbA1c level without hypoglycemia as compared to NPH + OAD (RR = 1.32 [1.09, 1.59]) or MIX without OAD (RR = 1.61 [1.22, 2.13]) and similar effect as IDet + OAD (RR = 1.07 [0.87, 1.33]) and MIX + OAD (RR = 1.09 [0.86, 1.38]). IGlar + OAD demonstrated significantly lower risk of symptomatic hypoglycemia as compared to NPH + OAD (RR = 0.89 [0.83, 0.96]), MIX + OAD (RR = 0.75 [0.68, 0.83]) and MIX without OAD(RR = 0.75 [0.68, 0.83]), but not with IDet + OAD (RR = 0.99 [0.90, 1.08]). In basal-bolus regimens, IGlar demonstrated similar proportion of T2DM patients achieving target HbA1c as compared to NPH (RR = 1.14 [0.91, 1.44]) but higher than MIX (RR = 1.26 [1.12, 1.42) or IDet (RR = 1.38 [1.11, 1.72]). The risk of severe hypoglycemia was lower in IGlar than in NPH (RR = 0.77 [0.63, 0.94]), with no differences in comparison with MIX (RR = 0.74 [0.46, 1.20]) and IDet (RR = 1.10 [0.54, 2.25]). IGlar + OAD has comparable safety profile to NPH, with less frequent adverse events leading to treatment discontinuation than MIX + OAD (RR = 0.41 [0.22, 0.76]) and IDet + OAD (RR = 0.40 [0.24, 0.69]). Also severe adverse reactions were less common for IGlar + OAD when compared to MIX + OAD (RR = 0.71 [0.52; 0.98]). CONCLUSION: For the majority of examined efficacy and safety outcomes, IGlar use in T2DM patients was superior or non-inferior to the alternative insulin treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Today, more effective and better tolerated drugs are available [[205], [206], [207]].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [206]
In the citing paper
“Pharmacotherapy for diabetes mellitus began with several drugs that were poorly tolerated or that had adverse side effects.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [206]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · cited 2×
“Search strategy Following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines, clinical evidence was identified through a systematic search of major databases of medical information, including Medline (via PubMed), EMBASE and the Cochrane Central Register of Controlled Trials [35…”
MethodPreferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582 · cited 1×
“Higher number of granted points reflected higher credibility of a clinical trial [37].”
BackgroundZhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J. P. T., Green, S. R., & Higgins, J. P. T. (2008) · Cited by 7,171
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,540
Calamita, E., Schmid, M., Kunz, M., Ndebele-Murisa, M. R., Magadza, C. H. D., Nyambe, I., & Wehrli, B. (2019) · Figshare · doi:10.26181/6153922fe919c · Cited by 4,222
Scottish Intercollegiate Guidelines Network
Twaddle, S., & Qureshi, S. (2005) · Evidence-based Healthcare and Public Health · doi:10.1016/j.ehbc.2005.09.008 · Cited by 4,084
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636 · cited 1×
“Such analysis would have been of potential clinical importance taking into account earlier studies searching for potential association between T2DM and pharmacological therapies used for its treatment and the risk of cancer [75–81].”
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479 · cited 2×
“Riddle [44] Sanofi-Aventis Adequate Open labeled Sufficient Adequate mITT 3/5”
BackgroundSevere hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471 · cited 10×
“M as si -B en d et ti [4 5 ] M u lt ic en te r 2 8 9 v s.”
BackgroundInfluentialIntensive glucose control and macrovascular outcomes in type 2 diabetes
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1470-0 · Cited by 1,189 · cited 8×
“E sp o si to [4 8 ] M u lt ic en te r 5 5 v s.”
BackgroundInfluentialGlobal guideline for type 2 diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.001 · Cited by 1,064
Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818 · cited 11×
“IGlar has favorable pharmacokinetic and pharmacodynamics properties that allow providing constant insulin activity over 24 h with only a single injection, and is the most widely prescribed LAA [12].”
BackgroundInfluential(2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.10.013 · Cited by 609
[Management of hyperglycaemia in type 2 diabetes: a patient-centered approach].
Scheen, A. J., & Mathieu, C. (2012) · PubMed · Cited by 581
Initiating Insulin Therapy in Type 2 Diabetes
Raskin, P., Allen, E., Hollander, P., Lewin, A., Gabbay, R. A., Hu, P., Bode, B., Garber, A., & for the INITIATE Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.2.260 · Cited by 560 · cited 1×
“Raskin [57] Novo Nordisk Properly described Open labeled Sufficient Unclear mITT 2/5”
BackgroundHandelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S., Davidson, J. A., Einhorn, D., Ganda, O., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.s2.1 · Cited by 513 · cited 3×
“be chosen individually to patient’s needs in order to achieve treatment goals and maintain its safety [1, 2].”
BackgroundBasal Insulin Therapy in Type 2 Diabetes
Rosenstock, J., Schwartz, S. L., Clark, C. M., Park, G. D., Donley, D. W., & Edwards, M. B. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.631 · Cited by 478 · cited 3×
“Rosenstock [47] Sanofi-Aventis No description Open labeled Sufficient Unclear ITT 2/5”
BackgroundMethodRosenstock, J., Davies, M., Home, P. D., Larsen, J., Koenen, C., & Schernthaner, G. (2008) · Diabetologia · doi:10.1007/s00125-007-0911-x · Cited by 447 · cited 2×
“ment in two RCTs [65, 66] and according to basal ? bolus scheme in the remaining two [67, 68].”
ResultInsulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study
Yki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Tulokas, T., Hulme, S., Hardy, K., McNulty, S., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0132-0 · Cited by 434 · cited 2×
“Yki-Järvinen [43] Sanofi-Aventis Adequate Open labeled Sufficient Unclear mITT 3/5”
BackgroundJanka, H. U., Plewe, G., Riddle, M. C., Kliebe-Frisch, C., Schweitzer, M. A., & Yki-Järvinen, H. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.254 · Cited by 414 · cited 3×
“Severe hypoglycemia was uncommon in both arms [53, 54].”
Reduced Hypoglycemia Risk With Insulin Glargine
Rosenstock, J., Dailey, G., Massi-Benedetti, M., Fritsche, A., Lin, Z., & Salzman, A. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.950 · Cited by 371 · cited 1×
“, insulin glargine with insulin detemir and premixed insulin analogs with human biphasic insulins [16, 19, 23, 25, 26, 29, 31, 33, 70].”
BackgroundHorvath, K., Jeitler, K., Berghold, A., Ebrahim, S. H., Gratzer, T. W., Plank, J., Kaiser, T., Pieber, T. R., & Siebenhofer, A. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005613.pub3 · Cited by 366 · cited 1×
“, insulin glargine with insulin detemir and premixed insulin analogs with human biphasic insulins [16, 19, 23, 25, 26, 29, 31, 33, 70].”
BackgroundFritsche, A., Schweitzer, M. A., Hring, H.-U., & and the 4001 Study Group* (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-12-200306170-00006 · Cited by 331
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320 · cited 2×
“Finally, several reviews did not attempt to accumulate included studies and presented only qualitative assessment, which significantly limited accuracy and precision of the conclusions [21, 24, 26, 28, 30, 32, 34].”
BackgroundResultHsu, P.-F., Sung, S.-H., Cheng, H.-M., Yeh, J.-S., Liu, W.-L., Chan, W.-L., Chen, C.-H., Chou, P., & Chuang, S.-Y. (2013) · Diabetes Care · doi:10.2337/dc12-0916 · Cited by 249
Long-acting insulin analogues versus NPH human insulin in type 2 diabetes
Monami, M., Marchionni, N., & Mannucci, E. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.04.007 · Cited by 211 · cited 1×
“, insulin glargine with insulin detemir and premixed insulin analogs with human biphasic insulins [16, 19, 23, 25, 26, 29, 31, 33, 70].”
BackgroundAdvancing Insulin Therapy in Type 2 Diabetes Previously Treated With Glargine Plus Oral Agents
Rosenstock, J., Ahmann, A. J., Colon, G., Scism-Bacon, J., Jiang, H., & Martin, S. (2008) · Diabetes Care · doi:10.2337/dc07-1122 · Cited by 191
Epidemiological aspects of neoplasms in diabetes
Nicolucci, A. (2010) · Acta Diabetologica · doi:10.1007/s00592-010-0187-3 · Cited by 162 · cited 1×
“Such analysis would have been of potential clinical importance taking into account earlier studies searching for potential association between T2DM and pharmacological therapies used for its treatment and the risk of cancer [75–81].”
BackgroundHollander, P., Cooper, J., Bregnhøj, J., & Pedersen, C. B. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.11.001 · Cited by 161 · cited 2×
“Hollander [67] Novo Nordisk Adequate Open labeled Sufficient Adequate mITT 3/5”
BackgroundResultSwinnen, S. G., Dain, M.-P., Aronson, R., Davies, M., Gerstein, H. C., Pfeiffer, A. F., Snoek, F. J., DeVries, J. H., Hoekstra, J. B., & Holleman, F. (2010) · Diabetes Care · doi:10.2337/dc09-2294 · Cited by 159
Mullins, P. R., Sharplin, P., Yki‐Järvinen, H., Riddle, M. C., & Häring, H. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.08.020 · Cited by 156 · cited 1×
“These results are consistent with most of the available systematic reviews comparing IGlar and NPH, which reported similar effect on HbA1c level with concomitantly lower risk of hypoglycemia for IGlar, particularly in terms of nocturnal events [18, 20, 21, 28].”
ResultMassi Benedetti, M., Humburg, E., Dressler, A., Ziemen, M., & for the 3002 Study Group (2003) · Hormone and Metabolic Research · doi:10.1055/s-2003-39080 · Cited by 149 · cited 4×
“Massi-Bendetti [45] Grant from Hoechst Marion Russel Deutschland Clinical Development Adequate Open labeled Sufficient Adequate mITT 3/5”
BackgroundInfluentialA review of human and analogue insulin trials
Gough, S. C. L. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.10.015 · Cited by 148 · cited 1×
“Finally, several reviews did not attempt to accumulate included studies and presented only qualitative assessment, which significantly limited accuracy and precision of the conclusions [21, 24, 26, 28, 30, 32, 34].”
BackgroundInsulin detemir versus insulin glargine for type 2 diabetes mellitus
Swinnen, S. G., Simon, A. C., Holleman, F., Hoekstra, J. B., & DeVries, J. H. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006383.pub2 · Cited by 137 · cited 2×
“, insulin glargine with insulin detemir and premixed insulin analogs with human biphasic insulins [16, 19, 23, 25, 26, 29, 31, 33, 70].”
BackgroundDURAbility of Basal Versus Lispro Mix 75/25 Insulin Efficacy (DURABLE) Trial 24-Week Results
Buse, J. B., Wolffenbuttel, B. H. R., Herman, W. H., Shemonsky, N. K., Jiang, H. H., Fahrbach, J. L., Scism-Bacon, J. L., & Martin, S. A. (2009) · Diabetes Care · doi:10.2337/dc08-2117 · Cited by 126 · cited 4×
“No evidence for the difference between IGlar and MIX with respect to both overall adverse events and treatment associated adverse events was found regardless of treatment schemes that were directly compared.”
BackgroundInfluentialKarlstad, O., Linde, J., Vestergaard, P., Hjellvik, V., Bazelier, M., Schmidt, M., Andersen, M., Auvinen, A., Haukka, J., Furu, K., et al. (2013) · Current Drug Safety · doi:10.2174/15680266113136660067 · Cited by 116 · cited 1×
“Such analysis would have been of potential clinical importance taking into account earlier studies searching for potential association between T2DM and pharmacological therapies used for its treatment and the risk of cancer [75–81].”
BackgroundTherapy in Type 2 Diabetes: Insulin Glargine vs. NPH Insulin Both in Combination with Glimepiride
Eliaschewitz, F. G., Calvo, C., Valbuena, H., Ruiz, M., Aschner, P. J., Villena, J. E., Ramirez, L. A., & Jiménez, J. T. (2006) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.10.015 · Cited by 115 · cited 2×
“Eliaschewitz [41] Sanofi-Aventis No description Open labeled Sufficient Unclear mITT 2/5”
BackgroundOakley, W. (1950) · BMJ · doi:10.1136/bmj.1.4648.287-a · Cited by 114
Raskin, P., Gylvin, T., Weng, W., & Chaykin, L. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.989 · Cited by 113 · cited 2×
“Raskin [68] Novo Nordisk No description Open labeled Insufficient Unclear mITT 1/5”
BackgroundResultKann, P., Wascher, T., Zackova, V., Moeller, J., Medding, J., Szocs, A., Mokan, M., Mrevlje, F., & Regulski, M. (2006) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2006-949655 · Cited by 111 · cited 1×
“Kann [56] Novo Nordisk Properly described Open labeled Insufficient Unclear mITT 1/5”
BackgroundQayyum, R., Bolen, S., Maruthur, N., Feldman, L., Wilson, L. M., Marinopoulos, S. S., Ranasinghe, P., Amer, M., & Bass, E. B. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-8-200810210-00242 · Cited by 107 · cited 2×
“Available systematic reviews showed that MIX, as compared to LAA, was associated with better glycemic control but also with a higher incidence of hypoglycemia [23, 33].”
BackgroundFritsche, A., Larbig, M., Owens, D., Häring, H. ‐., & on behalf of the GINGER study group (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01165.x · Cited by 102 · cited 4×
“Premixed insulin analogs were used as comparators in most RCTs, except for participants of trials comparing IGlar ? OAD with mix monotherapy [52–54] and 59 % of subjects from another study assessing basal ? bolus regimen in comparison with MIX [62], who were treated with human premixed insulins.”
BackgroundMethodInfluentialColmers-Gray, I. N., Bowker, S. L., Tjosvold, L., & Johnson, J. A. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.08.011 · Cited by 94 · cited 1×
“Such analysis would have been of potential clinical importance taking into account earlier studies searching for potential association between T2DM and pharmacological therapies used for its treatment and the risk of cancer [75–81].”
BackgroundIlag, L. L., Kerr, L., Malone, J. K., & Tan, M. H. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.003 · Cited by 88 · cited 2×
“Finally, several reviews did not attempt to accumulate included studies and presented only qualitative assessment, which significantly limited accuracy and precision of the conclusions [21, 24, 26, 28, 30, 32, 34].”
BackgroundRosenstock, J., Fonseca, V., McGill, J. B., Riddle, M., Hallé, J.-P., Hramiak, I., Johnston, P., & Davis, M. (2009) · Diabetologia · doi:10.1007/s00125-009-1415-7 · Cited by 87 · cited 3×
“However, this study was not included in quantitative analysis due to heterogeneous treatment and much longer follow-up (260 weeks) when compared to the remaining RCTs [51].”
BackgroundMethodResultInfluentialSystematic review and meta-analysis of insulin therapy and risk of cancer
Janghorbani, M., Dehghani, M., & Salehi-Marzijarani, M. (2012) · Hormones and Cancer · doi:10.1007/s12672-012-0112-z · Cited by 86 · cited 1×
“Such analysis would have been of potential clinical importance taking into account earlier studies searching for potential association between T2DM and pharmacological therapies used for its treatment and the risk of cancer [75–81].”
BackgroundStrojek, K., Bebakar, W. M. W., Khutsoane, D. T., Pesic, M., Šmahelová, A., Thomsen, H. F., & Kalra, S. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903354674 · Cited by 83 · cited 1×
“Strojek [59] Novo Nordisk Adequate Open labeled Sufficient Adequate mITTi PP 3/5”
BackgroundBazzano, L. A., Lee, L. J., Shi, L., Reynolds, K., Jackson, J. A., & Fonseca, V. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02517.x · Cited by 80 · cited 1×
“These results are consistent with most of the available systematic reviews comparing IGlar and NPH, which reported similar effect on HbA1c level with concomitantly lower risk of hypoglycemia for IGlar, particularly in terms of nocturnal events [18, 20, 21, 28].”
ResultRobbins, D. C., Beisswenger, P. J., Ceriello, A., Goldberg, R. B., Moses, R. G., Pagkalos, E., Miličević, Z., Jones, C. A., Sarwat, S., & Tan, M. H. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.11.016 · Cited by 69
Opportunities and Challenges for Biosimilars: What's on the Horizon in the Global Insulin Market?
Rotenstein, L. S., Ran, N. A., Shivers, J. P., Yarchoan, M. M., & Close, K. L. (2012) · Clinical Diabetes · doi:10.2337/diaclin.30.4.138 · Cited by 61 · cited 1×
“The first developed and most commonly prescribed LAA product is glargine (IGlar) [14].”
BackgroundEsposito, K., Ciotola, M., Maiorino, M. I., Gualdiero, R., Schisano, B., Ceriello, A., Beneduce, F., Feola, G., & Giugliano, D. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-8-200810210-00005 · Cited by 51 · cited 4×
“However, all these studies were analyzed together as NPL demonstrates similar pharmacokinetic and pharmacodynamic properties to NPH [50].”
BackgroundInfluentialMiser, W. F., Arakaki, R. F., Jiang, H. H., Scism-Bacon, J. L., Anderson, P. W., & Fahrbach, J. L. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.05.001 · Cited by 49
DAILEY, G. E., Admane, K., Mercier, F., & Owens, D. R. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0063 · Cited by 49 · cited 2×
“Since numerous systematic reviews have been published in order to combine the outcomes of many RCTs comparing IGlar with various comparators, the additional value of our metaanalysis will be hereby discussed [16–34, 70].”
BackgroundPractical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues
Rolla, A. R., & Rakel, R. E. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.07.003 · Cited by 49 · cited 1×
“Finally, several reviews did not attempt to accumulate included studies and presented only qualitative assessment, which significantly limited accuracy and precision of the conclusions [21, 24, 26, 28, 30, 32, 34].”
BackgroundPontiroli, A. E., Miele, L., & Morabito, A. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01543.x · Cited by 48 · cited 2×
“, insulin glargine with insulin detemir and premixed insulin analogs with human biphasic insulins [16, 19, 23, 25, 26, 29, 31, 33, 70].”
BackgroundResultPistrosch, F., Köhler, C. U., Schäper, F., Landgraf, W., Forst, T. M., & Hanefeld, M. (2013) · Acta Diabetologica · doi:10.1007/s00592-012-0451-9 · Cited by 48 · cited 1×
“Interestingly, it has been demonstrated that early basal insulin initiation with IGlar improves FPG control and beta-cell function when compared to prolonged continuation of solely oral therapy [15].”
BackgroundFluctuation of Serum Basal Insulin Levels Following Single and Multiple Dosing of Insulin Glargine
Gerich, J., Becker, R. H. A., Zhu, R., & Bolli, G. B. (2006) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.8.237 · Cited by 45 · cited 1×
“Neutral protamine Hagedorn (NPH) has been frequently chosen as the first-line insulin; however, its use is associated with the risk of both hyper- and hypoglycemic events [12, 13].”
BackgroundClinical Pharmacokinetics and Pharmacodynamics of Insulin Lispro Mixtures
Roach, P. J., & Woodworth, J. R. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241130-00003 · Cited by 44 · cited 1×
“However, all these studies were analyzed together as NPL demonstrates similar pharmacokinetic and pharmacodynamic properties to NPH [50].”
BackgroundBowering, K., Reed, V. A., Felício, J., Landry, J., Liang, J., & Oliveira, J. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03722.x · Cited by 39 · cited 5×
“No evidence for the difference between IGlar and MIX with respect to both overall adverse events and treatment associated adverse events was found regardless of treatment schemes that were directly compared.”
BackgroundInfluentialEfficacy of biphasic insulin aspart in patients with type 2 diabetes
Halimi, S., Raskin, P., Liebl, A., Kawamori, R., Fulcher, G., & Gao, Y. H. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.11.021 · Cited by 38 · cited 1×
“Finally, several reviews did not attempt to accumulate included studies and presented only qualitative assessment, which significantly limited accuracy and precision of the conclusions [21, 24, 26, 28, 30, 32, 34].”
BackgroundJain, S. M., Mao, X.-Q., Escalante-Pulido, M., Ворохобина, Н. В., López, I. S., & Ilag, L. L. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01287.x · Cited by 35 · cited 2×
“10]) [62, 63], symptomatic (2 RCTs; RR = 1.”
Fakhoury, W. K. H., Lockhart, I., Kotchie, R. W., Aagren, M., & LeReun, C. (2008) · Pharmacology · doi:10.1159/000149569 · Cited by 33 · cited 2×
“[17] reported an advantage of IDet over IGlar in relation to the risk of hypoglycemia, with comparable metabolic control as measured by HbA1c.”
ResultSchiel, R., & Müller, U. A. (2007) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2007-984445 · Cited by 30 · cited 5×
“No evidence for the difference between IGlar and MIX with respect to both overall adverse events and treatment associated adverse events was found regardless of treatment schemes that were directly compared.”
BackgroundInfluentialGitt, A. K., Bramlage, P., Binz, C., Krekler, M., Plate, T., Deeg, E., Tschöpe, D., & (for the DiaRegis Study Group) (2011) · European Journal of Preventive Cardiology · doi:10.1177/1741826711411104 · Cited by 29 · cited 5×
“R as k in [5 7 ] M u lt ic en te r 1 1 6 v s.”
BackgroundInfluentialDavidson, J. A., Lacaya, L. B., Jiang, H. H., Heilmann, C. R., Scism-Bacon, J. L., Gates, J. R., & Jackson, J. A. (2010) · Endocrine Practice · doi:10.4158/ep09285.or · Cited by 28 · cited 1×
“Trials recruiting only patients with non-caucasian ethnicity were not considered as race may potentially influence the effects of insulin therapy [36].”
BackgroundStrojek, K., Shi, C., Carey, M. A., & Jacober, S. J. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01257.x · Cited by 26 · cited 5×
“Strojek [49] Eli Lilly No description Open labeled Sufficient Unclear mITT 2/5”
BackgroundMethodInfluentialEsposito, K., Chiodini, P., Capuano, A., Petrizzo, M., Improta, M. R., & Giugliano, D. (2012) · Diabetes Care · doi:10.2337/dc12-0698 · Cited by 25 · cited 2×
“, insulin glargine with insulin detemir and premixed insulin analogs with human biphasic insulins [16, 19, 23, 25, 26, 29, 31, 33, 70].”
BackgroundResultDiabetes, insulin use, smoking, and pancreatic cancer mortality in Taiwan
Tseng, C. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0471-0 · Cited by 24 · cited 1×
“Such analysis would have been of potential clinical importance taking into account earlier studies searching for potential association between T2DM and pharmacological therapies used for its treatment and the risk of cancer [75–81].”
BackgroundChen, Y., Chen, Q., Wang, Z., & Zhou, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081594 · Cited by 24 · cited 1×
“Such analysis would have been of potential clinical importance taking into account earlier studies searching for potential association between T2DM and pharmacological therapies used for its treatment and the risk of cancer [75–81].”
BackgroundFonseca, V. A., Davidson, J. A., Home, P., Snyder, J., Jellinger, P. S., Toft, A. D., & Barnett, A. H. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.485087 · Cited by 23 · cited 2×
“Available systematic reviews showed that MIX, as compared to LAA, was associated with better glycemic control but also with a higher incidence of hypoglycemia [23, 33].”
BackgroundLong-Acting Insulin Analogs: A Review of “Real-World” Effectiveness in Patients with Type 2 Diabetes
Pollock, R. F., Erny-Albrecht, K. M., Kalsekar, A., Bruhn, D. F., & Valentine, W. J. (2011) · Current Diabetes Reviews · doi:10.2174/157339911794273892 · Cited by 20
Jansen, H. J., Vervoort, G., van der Graaf, M., & Tack, C. J. (2010) · PubMed · Cited by 20
Hsia, S. H. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.11.028 · Cited by 18 · cited 3×
“Nine studies compared IGlar versus NPH [39–47], while in two others, patients from the comparatory group received neutral protaminated insulin lispro (NPL) [48, 49].”
Forst, T. M., Larbig, M., Hohberg, C., Forst, S., Diessel, S., Borchert, M., Roth, W., & Pfützner, A. H. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01209.x · Cited by 18 · cited 3×
“Nine studies compared IGlar versus NPH [39–47], while in two others, patients from the comparatory group received neutral protaminated insulin lispro (NPL) [48, 49].”
BackgroundSaisho, Y., Kou, K., Tanaka, K., Abe, T., Shimada, A., Kawai, T., & Itoh, H. (2012) · Acta Diabetologica · doi:10.1007/s00592-012-0441-y · Cited by 17 · cited 1×
“Pharmacotherapy of T2DM usually starts from monotherapy with metformin, and it is further intensified by adding OADs of other classes or injectable GLP-1 agonists; nevertheless, many patients will eventually require insulin, usually beginning from one injection of basal insulin preparation [1, 2, 69].”
BackgroundPiatti, P. M., Marone, E. M., Mantero, M., Setola, E., Galluccio, E., Lucotti, P., Shehaj, E., Villa, V., Perticone, F., Venturini, M., et al. (2012) · Acta Diabetologica · doi:10.1007/s00592-012-0426-x · Cited by 14
Koivisto, V. A., Cleall, S., Pontiroli, A. E., & Giugliano, D. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01484.x · Cited by 12 · cited 3×
“Koivisto [46] Eli Lilly No description Open labeled Sufficient Unclear mITT and PP/mITT 2/5”
BackgroundClissold (2007) · Core evidence · doi:10.2147/ce.s7422 · Cited by 11 · cited 2×
“Finally, several reviews did not attempt to accumulate included studies and presented only qualitative assessment, which significantly limited accuracy and precision of the conclusions [21, 24, 26, 28, 30, 32, 34].”
BackgroundResultAl-Shaikh, A. R. (2006) · Cited by 5
Research works printed but not linked: 1
- Levien TL, Baker DE, White JR Jr, Campbell RK (2002) Insulin glargine: a new basal insulin. Ann Pharmacother 36:1019–1027 · doi:10.1345/aph.1a301 · Paper page
Cited by
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults
Lipscombe, L., Booth, G., Butalia, S., Dasgupta, K., Eurich, D. T., Goldenberg, R., Khan, N., MacCallum, L., Shah, B. R., & Simpson, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.034 · Cited by 246
Body Weight Considerations in the Management of Type 2 Diabetes
Apovian, C. M., Okemah, J., & O’Neil, P. M. (2019) · Advances in Therapy · doi:10.1007/s12325-018-0824-8 · Cited by 239
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update
Lipscombe, L., Butalia, S., Dasgupta, K., Eurich, D. T., MacCallum, L., Shah, B. R., Simpson, S., & Senior, P. A. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.08.001 · Cited by 153
Deprescribing antihyperglycemic agents in older persons: Evidence-based clinical practice guideline.
Farrell, B. J., Black, C. D., Thompson, W., McCarthy, L. M., Rojas‐Fernandez, C. H., Lochnan, H. A., Shamji, S., Upshur, R. E. G., Bouchard, M., & Welch, V. A. (2017) · Europe PMC (PubMed Central) · Cited by 213
Semlitsch, T., Engler, J., Siebenhofer, A., Jeitler, K., Berghold, A., & Horvath, K. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005613.pub4 · Cited by 80
Metadata
- Authors
- Rys, P., Wojciechowski, P., Rogoz-Sitek, A., Niesyczyński, G., Lis, J., Syta, A., & Malecki, M. T.
- Affiliations
- Sanofi (France) (FR)
- Jagiellonian University (PL)
- Corresponding author
- Malecki, Maciej T.
- Venue
- Acta Diabetologica
- Published
- 2015-01-14
- Volume
- 52
- Issue
- 4
- Pages
- 649-662
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- PMC
- PMC4506471
- OpenAlex
- W2016846562
- Cited by
- 101
- References
- 92
- Citations by year
- 2026: 2 · 2024: 6 · 2023: 8 · 2022: 9 · 2021: 18 · 2020: 7 · 2019: 14 · 2018: 14 · 2017: 11 · 2016: 8 · 2015: 4
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Acta Diabetologica (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, other-oa)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Funders
- Sanofi
- Novo Nordisk
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin glargine, NPH insulin, premixed insulin, insulin detemir, type 2 diabetes, basal insulin, HbA1c, glycemic control, hypoglycemia, oral antidiabetic drugs, insulin safety, insulin analogues, insulin sensitivity
- MeSH terms
- Insulin Glargine, Insulin Detemir, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin, Isophane, Randomized Controlled Trials as Topic, Treatment Outcome, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
